Human LAMP5 / BAD-LAMP Protein, His Tag

Catalog # LA5-H52H9

Synonym

Source

Human LAMP5, His Tag (LA5-H52H9) is expressed from human 293 cells (HEK293). It contains AA Glu 30 - Glu 235 (Accession # Q9UJQ1-1).
Predicted N-terminus: Glu 30

Molecular Characterization



This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 25 kDa. The protein migrates as 31-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Human LAMP5, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Background

LAMPs (lysosome associated membrane proteins) represent a family of glycosylated proteins present predominantly on the membrane of lysosomes whose expression can vary among different tissues, suggesting a separation of functions. LAMP5 is expressed highly and specifically in MLL-r leukemia. LAMP5 is a direct target of the oncogenic MLL-fusion protein. LAMP5 depletion significantly inhibited leukemia cell growth in vitro and in vivo. Functional studies showed that LAMP-5 is a novel modulator of innateimmune pathways in MLL-r leukemias. Downregulation of LAMP5 led to inhibition of NF-κB signaling and increased activation of type-1 interferon signaling downstream of Toll-like Receptor/Interleukin 1 Receptor activation.

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.